Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

24.01 +0.55 (+2.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Celebrates Skin Cancer Awareness Month
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council
From Castle Biosciences, Inc.
Via Business Wire
Looking Into Castle Biosciences's Return On Capital Employed
 
Via Benzinga
Analyst Expectations for Castle Biosciences's Future
 
Via Benzinga
Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Reports First Quarter 2023 Results
From Castle Biosciences, Inc.
Via Business Wire
Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event
From Castle Biosciences, Inc.
Via Business Wire
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
From Castle Biosciences, Inc.
Via Business Wire
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
7 Value Stocks to Buy for Long-Term Growth
If you have the patience to ride out some choppy weather, these value stocks to buy may offer significant upside later. 
Via InvestorPlace
Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
From Castle Biosciences, Inc.
Via Business Wire
Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
From Castle Biosciences, Inc.
Via Business Wire
Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
From Castle Biosciences, Inc.
Via Business Wire
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.